Document:

Exhibit 10.1

 

AGREEMENT AND WAIVER 

 

This AGREEMENT AND WAIVER
(this “Agreement”), dated as of December 30, 2022, is entered into by and among Knightscope, Inc., a Delaware corporation
(the “Company”), and the investor signatory below (the “Holder”). Unless otherwise specified herein,
capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Securities Purchase Agreement
(as defined below).

 

RECITALS

 

A.       The
Company and the Holder are parties to the Securities Purchase Agreement, dated as of October 10, 2022 (as may be amended, modified, restated
or supplemented from time to time, the “Securities Purchase Agreement”), pursuant to which the Holder purchased from
the Company a Senior Secured Convertible Notes (the “Original Note”), with such outstanding principal as of the date
hereof as set forth on the signature page of the Holder attached hereto.

 

B.       The
Company desires (i) that the Holder waive, in part, 16(t)(i) of the Original Note such that (x) during the period commencing on
January 1, 2023 through, and including February 14, 2023, “$3 million” (as used in 16(t)(i) of the Original Note) shall
be reduced to $1.5 million (the “Initial Financial Covenant Waiver”), and (y) from and after February 14, 2023,
the Initial Financial Covenant Waiver shall no longer apply and the Available Cash (as defined in the Original Notes) limitation
shall revert back to $3 million; provided, that if the Company both (I) has filed a Universal Shelf Registration Statement on Form
S-3, including convertible notes, preferred stock, warrants and shares of Common Stock thereunder, with at least $25 million to $100
million of availability (to be determined by the Company with the advice of its professional advisors) (the “New Shelf
Registration Statement”) and (II) obtains the Stockholder Approval (as defined in the Securities Purchase Agreement) and
the approval (together with the Stockholder Approval, the “Stockholder Approvals”) from the stockholders of the
Company for the issuance of up to an additional $10 million in additional senior secured convertible notes with terms substantially the same in all
material respects to the Original Note, as amended (the “Additional Notes” (except such Additional Notes may be issued by the
Company pursuant to the New Shelf Registration Statement with such transaction documents correspondingly adjusted accordingly, mutatis
mutandis), collectively with the Original Note, the “Notes”), then, thereafter, “$3 million” (as
used in 16(t)(i) of the Original Note) shall be reduced back down to $1.5 million for the remaining term of the Notes (such
conditions in clauses (I) and (II) above, the “Conditional Financial Covenant Waiver Conditions”, and such
waiver, the “Conditional Financial Covenant Waiver”), (ii) effective upon, and contingent on the continued
satisfaction of, the Conditional Financial Covenant Waiver Conditions, the Holder shall waive, in part, Section 4.13(a) of the
Securities Purchase Agreement and Section 16(b) of the Original Notes, solely to permit a Reg A offering of (x) up to $20 million in
unsecured convertible notes, with a maturity date no earlier than the six month anniversary of the Maturity Date (as defined in the Notes), with a fixed conversion price of $10.00 (as adjusted for stock splits, stock dividends, recapitalizations and
similar events) (the “Reg A Bonds”), issued without any original issue discount for a cash purchase price equal
to no less than the face value of the Reg A Bonds; provided, that (A) the offering of Reg A Bonds may not be a Variable Rate
Transaction, (B) the holders of the Reg A Bonds (including any trustee or similar representative) shall execute and deliver to the
Holder a subordination agreement, in form and substance acceptable to the Holder, including, without limitation, that the holders of
Reg A Bonds shall not be permitted to receive any cash amount, directly or indirectly, with respect to the Reg A Bonds (including,
without limitation, whether pursuant to any acceleration, amortization, required redemption, interest or at maturity, as applicable)
at any time prior to the six month anniversary after no Notes remain outstanding (the “Reg A Waiver”); provided,
that at any time less than $2.5 million in aggregate amounts remain outstanding under the Notes, the Company shall be permitted to
pay cash interest on the Reg A Bonds at an annual rate not to exceed 12% per annum at any time during the term of the Reg A Bonds so
long as no Event of Default has occurred and is continuing and (iii) in accordance with Section 7(e) of the Notes, to lower the
Conversion Price, in part, such that the Conversion Price in effect on any given time of determination shall equal the Alternate
Conversion Price then in effect (but with 85% replacing 80% in such definition of Alternate Conversion Price, as applicable) (the
 “Conversion Price Adjustment”, and such price, each an “Adjusted Alternate Conversion
Price”).

 

     

     

    

 

TERMS OF AGREEMENT

 

In consideration of the premises
and further valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                 
Waivers. Effective as of the Effective Time, Initial Financial Covenant Waiver shall occur. Effective upon the Company’s
satisfaction in full of the Conditional Financial Covenant Waiver Conditions, the Conditional Financial Covenant Waiver and the Reg A
Waiver shall occur. In addition, the Investor hereby waives the Company’s compliance with Section 4.20(b) of the Securities Purchase
Agreement from the date hereof until February 28, 2023.

 

2.                 
Conversion Price Adjustment. Effective as of January 1, 2023, the Conversion Price Adjustment shall occur.

 

3.                 
Representations and Warranties.

 

(a)       Company
Bring Down. Except as set forth on Schedule 3(a) attached hereto, the Company hereby makes the representations and warranties to the
Holder as set forth in Section 3 of the Securities Purchase Agreement (as amended hereby) as if such representations and warranties were
made as of the date hereof and as of the Effective Time as set forth in their entirety in this Amendment, mutatis mutandis. Such
representations and warranties to the transactions thereunder and the securities issued pursuant thereto are hereby deemed for purposes
of this Agreement to be references to the transactions hereunder and the issuance of the securities pursuant hereto, references therein
to “Closing Date” being deemed references to the Effective Time, and references to “the date hereof” being deemed
references to the date of this Agreement.

 

(b)       Holder
Bring Down. The Holder hereby makes the representations and warranties to the Company as set forth in the Securities Purchase
Agreement (as amended hereby) as if such representations and warranties were made as of the date hereof and as of the Effective Time
as set forth in their entirety in this Amendment, mutatis mutandis. Such representations and warranties to the transactions
thereunder and the securities issued pursuant thereto are hereby deemed for purposes of this Agreement to be references to the
transactions hereunder and the issuance of the securities pursuant hereto, references therein to “Closing Date” being
deemed references to the Effective Time, and references to “the date hereof” being deemed references to the date of this
Agreement. Holder has good and valid title to the Original Note free and clear of any lien, mortgage, security interest, pledge,
charge or encumbrance of any kind (other than with respect to a bona fide margin account in the ordinary course of business).

 

    2

     

    

 

4.                 
Holder Right of First Offer. At any time after the time of initial satisfaction of the Conditional Financial Covenant
Waiver Conditions, if Holder delivers a written notice to the Company offering to purchase up to $10 million in Additional Notes, the
Company shall not consummate a Subsequent Placement (other than Excluded Securities) until the time of consummation or abandonment of
an offering with respect thereto.

 

5.                 
Disclosure of Transaction. The Company shall, on or before 9:30 a.m., New York City Time, on or prior to the first
business day after the date of this Agreement, file a Current Report on Form 8-K describing the terms of the transactions contemplated
hereby in the form required by the 1934 Act and attaching this Agreement as exhibits to such filing (excluding schedules, the “8-K
Filing”). From and after the filing of the 8-K Filing, the Company shall have disclosed all material, non-public information
(if any) provided up to such time to the Holder by the Company or any of its Subsidiaries or any of their respective officers, directors,
employees or agents. In addition, upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement with respect to the transactions contemplated hereby or as otherwise disclosed in the 8-K Filing,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees
or agents, on the one hand, and any of the Holder or any of their affiliates, on the other hand, shall terminate. Neither the Company,
its Subsidiaries nor the Holder shall issue any press releases or any other public statements with respect to the transactions contemplated
hereby; provided, however, the Company shall be entitled, without the prior approval of the Holder, to issue a press release or make such
other public disclosure with respect to such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith
or (ii) as is required by applicable law and regulations (provided that in the case of clause (i) the Holder shall be consulted by the
Company in connection with any such press release or other public disclosure prior to its release). Without the prior written consent
of the Holder (which may be granted or withheld in the Holder’s sole discretion), except as required by applicable law, the Company
shall not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of the Holder in any filing, announcement,
release or otherwise.

 

6.                 
Fees. The Company shall reimburse Kelley Drye & Warren, LLP (counsel to the lead Holder) in an aggregate non-accountable
amount of $15,000 (the “Legal Fee Amount”) for costs and expenses incurred by it in connection with drafting and negotiation
of this Agreement. Each party to this Agreement shall bear its own expenses in connection with the structuring, documentation, negotiation
and closing of the transactions contemplated hereby, except as provided in the previous sentence and except that the Company shall be
responsible for the payment of any placement agent’s fees, financial advisory fees, transfer agent fees, Depository Trust Company
fees relating to or arising out of the transactions contemplated hereby.

 

    3

     

    

 

7.                  Most
Favored Nation. The Company hereby represents and warrants as of the date hereof and covenants and agrees that none of the
terms offered to any Person with respect to any amendment, modification, waiver or exchange of any warrant to purchase Common Stock
(or other similar instrument), including, without limitation with respect to any consent, release, amendment, settlement, or waiver
relating thereto (each an “Settlement Document”), is or will be more favorable to such Person (other than any
reimbursement of legal fees) than those of the Holder and this Agreement. If, and whenever on or after the date hereof, the Company
enters into a Settlement Document, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence
thereof and (ii) the terms and conditions of this Agreement shall be, without any further action by the Holder or the Company,
automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit
of the more favorable terms and/or conditions (as the case may be) set forth in such Settlement Document, provided that upon written
notice to the Company at any time the Holder may elect not to accept the benefit of any such amended or modified term or condition,
in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect immediately prior to
such amendment or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of
this Section 7 shall apply similarly and equally to each Settlement Document.

 

8.                 
Effective Time. Except as otherwise set forth in this Section 8, this Agreement shall be effective (the “Effective
Time”) upon the later of (a) the time of due execution and delivery by the Company and the Holder of this Agreement, (b) the
time of due execution and delivery to the Holder of a consent of at least 50.1% of the stockholders of the Company to the Stockholder
Approval and (c) the time of payment of the Legal Fee Amount to Kelley Drye & Warren LLP.

 

9.                 
Ratification. Except as otherwise expressly provided herein, the Transaction Documents, are, and shall continue to
be, in full force and effect and are hereby ratified and confirmed in all respects.

 

10.             
Miscellaneous. Article V of the Securities Purchase Agreement (as amended hereby) is hereby incorporated by reference
herein, mutatis mutandis.

[Signature
Page Follows]

 

    4

     

    

 

       IN
WITNESS WHEREOF, the Holder and the Company have caused their respective signature page to this Agreement and Waiver to be duly executed
as of the date first written above.

 

	 	KNIGHTSCOPE, INC.
	 	 	 
	 	By:	/s/ Mallorie Burak
	 	 	Name: Mallorie Burak  
	 	 	Title:  EVP and CFO

 

     

     

    

 

IN WITNESS WHEREOF, the Holder and the Company
have caused their respective signature page to this Agreement and Waiver to be duly executed as of the date first written above.

 

	 	ALTO OPPORTUNITY MASTER FUND, SPC - SEGREGATED MASTER PORTFOLIO B
	 	 	 
	 	By:	/s/ Waqas Khatri
	 	 	Name:  Waqas Khatri
	 	 	Title:   Director

 

	 	Outstanding Principal Amount of Original Note
	 	 
	 	$6,075,000.00Exhibit 10.1

  

  

    Execution Version

    

    

    SHARE TRANSFER AGREEMENT

     

    This Share Transfer Agreement (this “Agreement”) is made effective as of
      December 30, 2022 (the “Effective Date”), by and between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and Merck KGaA, Darmstadt, Germany, a corporation with general partners organized under German law (the “Investor”).

     

    

    WHEREAS, simultaneously with the execution of this Agreement, the Company and the Investor are entering into a License Agreement dated as of the
      Effective Date (the “License Agreement”) under which the Company is licensing certain technology from the Investor;

     

    

    WHEREAS, the Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
      by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange
      Commission (the “Commission”) under the Securities Act; and

     

    

    WHEREAS, the License Agreement provides that, among other things, the Company will issue to the Investor shares of common stock, par value $0.00033
      per share (the “Common Stock”), of the Company upon the terms and conditions stated in this Agreement.

     

    

    NOW, THEREFORE, in consideration of the mutual covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency
      of which is acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:

     

    

    1. Issuance

          of Shares.

     

    

    1.1. Shares; Number of Shares. In consideration of the licenses and rights granted to the Company under the License Agreement, and subject to the terms and conditions of this Agreement and in reliance on the representations and
      warranties of the Investor set forth herein, the Company hereby agrees to issue to the Investor, and the Investor hereby agrees to acquire from the Company, such number of shares of the Common Stock (the “Shares”) equal to the quotient of US $5,000,000.00 divided by the closing price of a share of the Common Stock on the
      Nasdaq Capital Market on the Effective Date, rounded down to the nearest whole share. The Company shall not issue to Investor any number of shares that would exceed four point ninety-nine percent (4.99%) of the total outstanding shares in the
      Company.

     

    

    1.2. Closing; Delivery of Shares. The issuance of the Shares shall take place on the Effective Date, remotely via the exchange of documents and signatures, or at such other time, date and place as the Company and the Investor
      mutually agree upon in writing (which time and place are designated as the “Closing”). On or before the Closing, the Company will cause the transfer agent for the Common
      Stock (the “Transfer Agent”) to issue the Shares to the Investor and to hold the Shares in book-entry form for the account of the Investor. The book entry for the Shares
      will be subject to a stop transfer order reflecting such the transfer restrictions referred to in Sections 3.4 and 3.5 of this Agreement. At the Closing, the Company will deliver to Investor a copy of Company’s irrevocable instructions to its Transfer Agent for the Common Stock instructing such Transfer Agent to register the issuance of
      the Shares to the Investor via book-entry.

    

    

    2.     Representations and Warranties of the Company. The Company hereby
      represents and warrants to the Investor that:

     

    

    2.1. Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to
      carry on its business as presently conducted or proposed to be conducted and to own or lease the properties and assets it now owns or holds under lease. The Company is duly qualified to transact business and is in good standing in each jurisdiction
      in which the failure so to qualify would, individually or in the aggregate, have a material adverse effect upon the general affairs, business, management, properties, operations, financial condition or results of operations of the Company. Assuming
      the accuracy of the representations of the Investor in Section 3 of this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws.

     

    

    
      1

      
        

    

    Execution Version

    

    

    2.2. Valid Issuance of Shares. The Shares to be issued hereunder by the Company have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will have been validly issued and will be
      fully paid and nonassessable, will not be subject to preemptive rights or other similar rights of stockholders of the Company, and will be free and clear of all liens (except for restrictions on transfer imposed by applicable securities laws or
      contained herein) and the holder thereof will not be subject to personal liability by reason of being such holder.

     

    

    2.2. Authorization; No Conflicts; Authority. This Agreement has been duly authorized, executed and delivered by the Company, and constitutes a valid, legal and binding obligation of the Company, enforceable in accordance with its
      terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity.

     

    

    3. Representations and Warranties of the Investor. The Investor hereby represents and warrants to the Company that:

     

    

    3.1. Authorization. This Agreement has been duly authorized, executed and delivered by the Investor, and constitutes a valid, legal and binding obligation of the Investor, enforceable in accordance with its terms, except as such
      enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity.

     

    

    3.2. Purchase Entirely for Own Account. The Investor is acquiring the Shares for investment, and not with a view to the resale or distribution of any part thereof, and the Investor has no present intention of selling, granting any
      participation in, or otherwise distributing the same. The Investor does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with
      respect to any of the Shares.

     

    

    3.3. Accredited Investor. The Investor is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

     

    

    3.4. Restricted Securities. The Investor understands that the Shares have not been registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon,
      among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein. The Investor understands that the Shares are “restricted

          securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Investor must hold the Shares
      indefinitely unless they are registered under the Securities Act and qualified by state authorities, or an exemption from such registration and qualification requirements is available.

     

    

    3.5. Legends. The Investor understands that the Shares may bear one or all of the following legends:

     

    

    (a) “THE SHARES REPRESENTED HEREBY HAVE NOT
      BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
      RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

     

    

    (b) Any legend required by the securities
      laws of any state to the extent such laws are applicable to the Shares represented by the certificate, instrument, or book entry so legended.

     

    

    
      2

      
        

    

    Execution Version

     

    

    4. Miscellaneous.

     

    

    4.1. Entire Agreement; Amendments; Waivers. This Agreement, together with the License Agreement, constitutes the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other prior or
      contemporaneous written or oral agreements relating to the subject matter hereof existing between the parties hereto are expressly canceled. This Agreement may not be amended, modified or waived except by an instrument in writing signed by each of
      the parties hereto.

     

    

    4.2. Successors and Assigns. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by either party without the prior written consent of the non-assigning party. The terms and conditions of this
      Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties hereto. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
      respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

     

    

    4.3. Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to
      evidence the fulfillment of the agreements herein contained.

     

    

    4.4. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of
      Delaware, without regard to the principles of conflicts of law thereof.

     

    

    4.5. Counterparts. This Agreement may be executed and delivered by facsimile, by electronic mail attaching a portable document file (.pdf) or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com). This Agreement may be executed in one or more counterparts
      and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument.

     

    

    4.6. Severability. If any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the parties will negotiate in good faith a valid, legal and enforceable substitute provision that most
      nearly reflects the original intent of the parties and all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed in order to carry out the intentions of the parties hereto as nearly as may
      be possible. Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such provision in any other jurisdiction.

     

    

    4.7. No Strict Construction. The language used in this Agreement is deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against a party.

    

    

    4.8.   Rule 144; Registration Statement. The Investor understands that
      the Shares must be held indefinitely unless such Shares are registered under the Securities Act or an exemption from registration is available. The Investor acknowledges that it is familiar with Rule 144 of the rules and regulations of the
      Commission, promulgated pursuant to the Securities Act (“Rule 144”), and that the Investor has been advised that Rule 144 permits resales under certain circumstances. The
      Investor understands that to the extent that Rule 144 is not available, the Investor will be unable to sell any Shares without either registration under the Securities Act or the existence of another exemption from such registration requirement.  The
      Company shall (i) make and keep available adequate current public information, as those terms are defined in Rule 144; (ii) use commercially reasonable efforts to file with the Commission in a timely manner all reports and other documents required of
      the Company under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and (iii) furnish to the Investor forthwith upon request (a)
      to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of Rule 144 and (b) such other information as may be reasonably requested to avail the Investor of any rule or regulation of the
      Commission that permits the selling of the Shares without registration.  Following expiration of the 180-day lock up period under the License Agreement (the “Lockup Period”),

      the Company shall promptly (within two (2) business days) have its legal counsel deliver an opinion to the Transfer Agent requesting removal of the stop transfer order and restrictive legend(s) appended to Investor’s book-entry statement(s). If,
      after the expiration of the Lockup Period, the Shares are not available for resale under Rule 144, the Company shall prepare and file, as promptly as practicable, with the Commission a registration statement of the Company filed under the Securities
      Act that covers the resale of the Shares for an offering to be made on a continuous basis pursuant to Rule 415 promulgated by the Commission pursuant to the Securities Act as such rule may be amended from time to time or any similar rule or
      regulation hereafter adopted by the Commission having substantially the same effect as such rule (“Rule 415”) or, if Rule 415 is not available for offers and sales of the
      Shares, by such other means of distribution of the Shares as the Investor may reasonably specify (the “Initial Registration Statement”). The Initial Registration Statement
      shall be on Form S-3, or if the Company is ineligible to register the Shares on Form S-3, such other form available to register for resale the Shares as a secondary offering.

     

    

    [Signature page follows]

     

    

    
      3

      
        

    

    IN WITNESS WHEREOF, the parties have executed this Share Transfer Agreement as of the Effective Date.

     

    

    	
            THE COMPANY:

          	
            PDS BIOTECHNOLOGY CORPORATION

          
	

          	

          	

          
	

          	
            By:

          	
            /s/ Frank Bedu-Addo

          	 
	

          	
            Name:

          	
            Frank Bedu-Addo, Ph.D.

          
	

          	
            Title:

          	
            Chief Executive Officer

          

     

    

    

    	
              INVESTOR:

          	
            Merck KGaA, Darmstadt, Germany

          	
             

          
	
             

          	
             

          	
             

          	
             

          
	 	
            By:  

          	
            /s/ Matthias Mullenbeck

          	
             

          
	 	
            Name:  

          	
            Dr. Matthias Mullenbeck, MBA

          	
             

          
	
             

          	
            Title:  

          	
            SVP, Head Global Business Development & Alliance Management

          	
             

          
	 	 	 	 
	 	
            By:

          	
            /s/ Jens Eckhardt

          	 
	 	
            Name:

          	
            Jens Eckhardt

          	 
	 	
            Title:

          	
            Authorized Representative

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]